AMGN Stock Recent News
AMGN LATEST HEADLINES
Amgen (AMGN) concluded the recent trading session at $311.55, signifying a +1.5% move from its prior day's close.
Amgen is a robust long-term investment due to its strong profitability, competitive moat, and promising pipeline, including an anti-obesity drug. Despite modest short-term growth guidance, AMGN's Horizon Therapeutics acquisition and innovation pipeline offer significant long-term potential. AMGN's 3.1% dividend yield, prudent debt management, and reasonable valuation make it an attractive 'buy and hold' stock.
Kevin Simpson, Capital Wealth Planning founder and CIO, joins CNBC's "Halftime Report" to detail his latest portfolio buys.
Dividend investing is an excellent strategy for (at least) two reasons. Companies that can provide consistent payouts generally have robust underlying operations.
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, biotechnology giant Amgen (AMGN 0.06%) has been the best-performing stock in 2025, returning an impressive 21% year to date.
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.
Karen Firestone, executive chairman at Aureus Asset Management, joins CNBC's "Halftime Report" to detail her latest stock purchases. The Investment Committee debate healthcare and biotech companies.
As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded down a wide variety of stocks in both fields.
In the latest trading session, Amgen (AMGN) closed at $314.38, marking a -0.53% move from the previous day.